PerkinElmer Selected for Expanded Neonatal Screening of Every Newborn in the Netherlands

Five Centers Will Expand Nationwide Screening from Three to 14
Disorders
BOSTON--(BUSINESS WIRE)--Nov. 6, 2006--PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today announced that it has been selected to provide neonatal screening technology to support an expanded screening program in the Netherlands. PerkinElmer will provide four tandem mass spectrometry-based systems, reagents and software to support the Netherlands' five hospital screening centers. The partnership expands the country's program - which is intended to reach each of the estimated 200,000 babies born annually in the Netherlands - from screening for three disorders to a total of 14 disorders.
"We are honored that the Netherlands has selected PerkinElmer technology to aid in this expanded national initiative to identify congenital disorders early," said Gregory L. Summe, chairman and chief executive officer of PerkinElmer, Inc. PerkinElmer recently announced that its technology was selected to expand newborn screening programs in Russia and Israel. "This agreement further fortifies PerkinElmer's leadership position in supplying neonatal screening technology and support to countries around the world." Summe noted that PerkinElmer has more than 10 years of experience with expanding newborn screening programs using tandem mass spectrometry and more than 20 years of experience in the field of newborn screening.
"Early intervention is critical," Summe noted. "There is broad recognition that simple and inexpensive screenings before a family leaves the hospital and before symptoms appear is highly preferable to responding once a condition has developed."
"A key consideration, given the number of babies to be screened in the Netherlands and the greater number of disorders being screened, was securing robust software that could support the system and manage the calculations," Summe added. He noted that up to 100 times more data items will need to be analyzed and reviewed daily. The Specimen Gate Data Suite laboratory information management system from PerkinElmer will allow the country's five screening centers to implement a solution that will electronically track laboratory workflow from sample receipt and preparation through analysis, quality control review, reporting and follow up to advance the pace and precision of the screening program.
PerkinElmer will support the program with comprehensive training, customer support and service to ensure total quality in every stage of the screening process. PerkinElmer is the only total solution provider with FDA and Commonwealth of Europe approval.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.
PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.5 billion in 2005, has 8,000 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

CONTACT: Investor Relations:
PerkinElmer, Inc.
Steven Delahunt, 781-431-4258
or
Media Contact:
Brodeur Worldwide
Steve Marchant, 617-587-2864

SOURCE: PerkinElmer, Inc.
 

http://phx.corporate-ir.net/phoenix.zhtml?c=89380&p=irol-pressRelease&t=Regular&id=927305&

      <----back